PCM
BPMC

Prelude Capital Management’s Blueprint Medicines BPMC Stock Holding History

Prelude Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$46K – 1335
2020
Q3 		$46K Buy
+500
New +$38.5K ﹤0.01% 1143

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's BPMC Position: Q3 2025 in Review

Prelude Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 60,154 shares — an estimated $7.71M sold.

Prelude Capital Management first reported a position in BPMC in Q2 2017 and held it in 11 quarters. The position peaked at $7.71M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Prelude Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 60,154 Blueprint Medicines shares in Q3 2025, an estimated $7.71M.
  • Prelude Capital Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 11 quarters.
  • Prelude Capital Management's Blueprint Medicines position peaked at $7.71M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.